Xeris closes $150M Hayfin debt facility, reports FY2021 product revenue $79M (+56%) and guides FY2022 $105M-$120M

Xeris Biopharma Holdings, Inc.

Xeris drew $100M from new $150M Hayfin term loan (9%+SOFR, warrants at $2.28, 5-yr maturity); repaid $43.5M Oxford/SVB debt.
FY2021 net product revenue $79M (pro forma), up 56% YoY; net loss $122.7M ($1.55/share) vs $91.1M ($2.14/share) in 2020.
FY2022 revenue guidance $105M-$120M; year-end cash $90M-$110M; cash flow breakeven targeted by end of 2023.
Gvoke prescriptions up 85% in Q4, retail share ~17%; Keveyis at high end of $38-40M guidance; Recorlev launched Feb 2022.

item 1.01 item 2.02 item 2.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.